Skip to main content

Advertisement

SpringerLink
Log in

Nutritional impact of active hexose-correlated compound for patients with resectable or borderline-resectable pancreatic cancer treated with neoadjuvant therapy

  • Short Communication
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

Active hexose-correlated compound (AHCC) is a standardized extract from cultured Lentinula edodes mycelia, used as a potent biological response modifier in cancer treatment. We evaluated the nutritional effect of AHCC, given during neoadjuvant therapy, to patients with pancreatic ductal adenocarcinoma (PDAC). Thirty patients with resectable or borderline-resectable PDAC received neoadjuvant therapy with gemcitabine plus S-1. We compared, retrospectively, the outcomes of 15 patients who received AHCC combined with neoadjuvant therapy with those of 15 patients who did not receive AHCC combined with neoadjuvant therapy. The median changes of the neutrophil-to-lymphocyte ratio (NLR) and prognostic nutrition index (PNI) were significantly better in the AHCC group. The relative dose intensity of neoadjuvant therapy was also significantly higher in the AHCC group. Thus, AHCC may improve the nutritional status during neoadjuvant therapy of patients with pancreatic ductal adenocarcinoma. To validate these results and examine the long-term impact of AHCC, a prospective phase II study for PDAC is ongoing.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Silvestris N, Longo V, Cellini F, Reni M, Bittoni A, Cataldo I, et al. Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma. Crit Rev Oncol Hematol. 2016;98:309–24.

    Article  Google Scholar 

  2. Hashimoto D, Chikamoto A, Ohmuraya M, Abe S, Nakagawa S, Beppu T, et al. Impact of postoperative weight loss on survival after resection for pancreatic cancer. J Parenter Enter Nutr. 2015;39:598–603.

    Article  Google Scholar 

  3. Trestini I, Paiella S, Sandini M, Sperduti I, Elio G, Pollini T, et al. Prognostic impact of preoperative nutritional risk in patients who undergo surgery for pancreatic adenocarcinoma. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08515-5.

    Article  PubMed  Google Scholar 

  4. Tashiro M, Yamada S, Sonohara F, Takami H, Suenaga M, Hayashi M, et al. Clinical impact of neoadjuvant therapy on nutritional status in pancreatic cancer. Ann Surg Oncol. 2018;25:3365–71.

    Article  Google Scholar 

  5. Matsushita K, Kuramitsu Y, Ohiro Y, Obara M, Kobayashi M, Li Y-Q, et al. Combination therapy of active hexose correlated compound plus UFT significantly reduces the metastasis of rat mammary adenocarcinoma. Anticancer Drugs. 1998;9:343–50.

    Article  CAS  Google Scholar 

  6. Hirose A, Sato E, Fujii H, Sun B, Nishioka H, Aruoma OI. The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice. Toxicol Appl Pharmacol. 2007;222:152–8.

    Article  CAS  Google Scholar 

  7. The ASCO post Active Hexose Correlated Compound [Internet]. Available from: https://ascopost.com/issues/march-10-2020/active-hexose-correlated-compound/. Accessed 16 Mar 2021.

  8. Yanagimoto H, Satoi S, Yamamoto T, Hirooka S, Yamaki S, Kotsuka M, et al. Alleviating effect of active hexose correlated compound (AHCC) on chemotherapy-related adverse events in patients with unresectable pancreatic ductal adenocarcinoma. Nutr Cancer. 2016;68:234–40.

    Article  CAS  Google Scholar 

  9. Matsui Y, Uhara J, Satoi S, Kaibori M, Yamada H, Kitade H, et al. Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort study. J Hepatol. 2002;37:78–86.

    Article  Google Scholar 

  10. Terakawa N, Matsui Y, Satoi S, Yanagimoto H, Takahashi K, Yamamoto T, et al. Immunological effect of active hexose correlated compound (AHCC) in healthy volunteers: a double-blind placebo-controlled trial. Nutr Cancer. 2008;60:643–51.

    Article  CAS  Google Scholar 

  11. Glazer ES, Rashid OM, Pimiento JM, Hodul PJ, Malafa MP. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma. Surgery. 2016;160:1288–93.

    Article  Google Scholar 

  12. Nakagawa S, Yamashita Y, Umezaki N, Yamao T, Okabe H, Imai K, et al. Serum marker score based on prognostic nutrition index, carcinoembryonic antigen, and carbohydrate antigen 19–9 is associated with recurrence for patients undergoing surgery for pancreatic ductal adenocarcinoma. Pancreas. 2018;47:1130–4.

    Article  CAS  Google Scholar 

  13. Satoi S, Unno M, Motoi F. The effect of neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic cancer (randomized phase II/III trial;Prep-02/JSAP-05). J Clin Oncol. 2019;37:abstr4126.

    Article  Google Scholar 

  14. Al Abbas AI, Zenati M, Reiser CJ, Hamad A, Jung JP, Zureikat AH, et al. Serum CA19-9 response to neoadjuvant therapy predicts tumor size reduction and survival in pancreatic adenocarcinoma. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-019-08156-3.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 [Internet]. Available from: http://www.jcog.jp/doctor/tool/ctcaev5.html. Accessed 16 Mar 2021.

  16. Kanda M, Fujii T, Kodera Y, Nagai S, Takeda S, Nakao A. Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg. 2011;98:268–74.

    Article  CAS  Google Scholar 

  17. A double-blind randomized phase II study of AHCC for patients with resectable / borderline resectable pancreatic cancer [Internet]. Available from: https://jrct.niph.go.jp/en-latest-detail/jRCTs051200029. Accessed 16 Mar 2021.

Download references

Acknowledgements

We thank Amino Up Chemical Co. Ltd for donating the active hexose-correlated compound (AHCC) for this study.

Funding

There is no source of any financial support in this study.

Author information

Authors and Affiliations

  1. Department of Surgery, Kansai Medical University, 2-5-1 Shin-machi, Hirakata-City, Osaka, 573-1010, Japan

    Daisuke Hashimoto, Sohei Satoi, Tomohisa Yamamoto, So Yamaki, Hironori Ryota, Tatsuma Sakaguchi, Satoshi Hirooka, Kentaro Inoue & Mitsugu Sekimoto

  2. Department of Pathology and Clinical Laboratory, Kansai Medical University, 2-5-1 Shin-machi, Hirakata-City, Osaka, 573-1010, Japan

    Mitsuaki Ishida

Authors
  1. Daisuke Hashimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sohei Satoi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tomohisa Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. So Yamaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mitsuaki Ishida
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hironori Ryota
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tatsuma Sakaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Satoshi Hirooka
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kentaro Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Mitsugu Sekimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sohei Satoi.

Ethics declarations

Conflict of interests

M Sekimoto received research funding from Amino Up Chemical Co. Ltd. The sponsor had no control over the interpretation, writing, or publication of this work.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

595_2021_2308_MOESM1_ESM.tif

Supplementary file1 Supplementary Fig. 1. Nutritional status before neoadjuvant therapy in the two groups. (A) NLR pre-NAT, and (B) PNI pre-NAT. AHCC, active hexose-correlated compound; NAT, neoadjuvant therapy; NLR, neutrophil-to-lymphocyte ratio; PNI, prognostic nutrition index (TIF 53 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hashimoto, D., Satoi, S., Yamamoto, T. et al. Nutritional impact of active hexose-correlated compound for patients with resectable or borderline-resectable pancreatic cancer treated with neoadjuvant therapy. Surg Today 51, 1872–1876 (2021). https://doi.org/10.1007/s00595-021-02308-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00595-021-02308-3

Keywords

Search

Navigation